Patents Issued in December 24, 2020
-
Publication number: 20200399286Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.Type: ApplicationFiled: May 15, 2020Publication date: December 24, 2020Applicant: Genentech, Inc.Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
-
Publication number: 20200399287Abstract: A visible light activated ink that produces a color change when exposed to visible light is provided. The ink includes a visible light activated photochromic compound, one or more binders, additives including one or more surfactants, and a solvent. The visible light activated ink is substantially colorless in the as-deposited state and requires a visible light intensity of approximately 300 W/m2 or greater at a wavelength of approximately 400-700 nm to produce a color change.Type: ApplicationFiled: June 22, 2020Publication date: December 24, 2020Inventors: Pui Keong CHOW, Faan Fung HUNG, Chenmin LIU, Chi Ho KWOK
-
Publication number: 20200399288Abstract: The present invention relates to 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.Type: ApplicationFiled: December 4, 2018Publication date: December 24, 2020Inventors: Laurent Provins, Hugues Chanteux
-
Publication number: 20200399289Abstract: An aromatic compound which improves emission efficiency and an organic electroluminescence device including the same are provided. The organic electroluminescence device includes: a first electrode; a second electrode opposite to the first electrode; and a plurality of organic layers between the first electrode and the second electrode, where at least one organic layer among the plurality of organic layers includes the aromatic compound. The aromatic compound is represented by Formula 1 below.Type: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Inventors: Heechoon Ahn, Soo-byung Ko, Mieun Jun, Sungbum Kim, Mina Jeon, Youngkook Kim, Seokhwan Hwang
-
Publication number: 20200399290Abstract: A nanocomposite containing azole modified hollow silica spheres. In particular, the nanocomposite involves a silanization reaction product of an azole-functionalized silane linker and hollow silica spheres. The azole-functionalized silane linker is produced via a ring-opening reaction a silane coupling agent having an epoxide group and an azole compound. A method of making the nanocomposite is also specified.Type: ApplicationFiled: June 21, 2019Publication date: December 24, 2020Applicant: Imam Abdulrahman Bin Faisal UniversityInventors: Sarah Mousa M. ASIRI, Ayhan Bozkurt
-
Publication number: 20200399291Abstract: A method of making an aminosilane, the method comprising: forming a reaction mixture comprising a hydridosilane, an amine and a dehydrogenative coupling catalyst in a reactor; subjecting the reaction mixture to conditions sufficient to cause a dehydrogenative coupling reaction between the hydridosilane and the amine to form the aminosilane and hydrogen gas; and venting the hydrogen gas; wherein the forming of the reaction mixture comprising the hydridosilane, the amine and the dehydrogenative coupling catalyst comprises continuously feeding the hydridosilane to the reactor containing the amine and the dehydrogenative coupling catalyst.Type: ApplicationFiled: February 13, 2019Publication date: December 24, 2020Inventors: Anthony E. Foss, Jesse A. Maddock, Brian D. Rekken, Michael D. Telgenhoff
-
Publication number: 20200399292Abstract: The present invention provides a composition for substrate surface modification and a method using the same, and the composition for substrate surface modification is composed of a compound of the general formula structure shown in formula 1: formula 1, wherein n1 is an integer of 1 to 6, and R is a zwitterionic group. The composition for substrate surface modification uses water as a medium to perform modifying reaction over a substrate surface, and at the same time has biological modification characteristics, and abilities of immobilizing biomolecules and anti-biofouling.Type: ApplicationFiled: September 3, 2020Publication date: December 24, 2020Inventors: Chen-Han HUANG, Wen-Hao CHEN
-
Publication number: 20200399293Abstract: The present invention provides a composition for substrate surface modification and a method using the same, and the composition for substrate surface modification is composed of a compound of the general formula structure shown in formula 1: formula 1, wherein n1 is an integer of 1 to 6, and R is a zwitterionic group. The composition for substrate surface modification uses water as a medium to perform modifying reaction over a substrate surface, and at the same time has biological modification characteristics, and abilities of immobilizing biomolecules and anti-biofouling.Type: ApplicationFiled: September 3, 2020Publication date: December 24, 2020Inventors: Chen-Han Huang, Wen-Hao Chen
-
Publication number: 20200399294Abstract: A process comprising: (a) contacting a feed stream comprising a di-alkyltin dihalide distillate with an alkylation agent, thereby forming an alkylated mixture comprising R4Sn and optionally R3SnX, R2SnX2, or mixtures thereof, where R is a linear, branched or cyclic C1-C20 alkyl, and X is a halide; (b) contacting the alkylated mixture with SnX4, thereby forming an alkyltin halide mixture comprising RSnX3, R2SnX2, and optionally impurities, R3SnX or mixtures thereof; (c) separating by distillation the alkyltin halide mixture to form a mono-alkyltin halide-rich distillate stream and a liquid di-alkyltin halide-rich bottoms stream comprising R2SnX2, RSnX3, and optionally impurities, R3SnX, or mixtures thereof; (d) separating by distillation the di-alkyltin halide-rich bottoms stream, thereby forming the liquid di-alkyltin dihalide distillate comprising R2SnX2, and optionally RSnX3, R3SnX or mixtures thereof, and an impurities-rich bottoms stream; and (e) recycling a part, xrecycle, of the liquid di-alkyltin diType: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Inventors: Peter FRENKEL, Joseph SALSBURY, Steven McKEOWN
-
Publication number: 20200399295Abstract: The invention provides a compound of formula (I) wherein B is a nucleobase; U is O or S; Rx is —OC(?O)Ry, —OC(?O)CH(Ry)NH2, —OCH2OC(?O)Ry; Ry is optionally substituted alkyl or alkenyl or the side chain of a natural or unnatural amino acid R1 is H, or optionally substituted phenyl, benzyl, naphthyl, pyridyl or indolyl, or Rx and R1 together define a bond thus forming a cyclic phosphate; R2 and R2? together define the side chain of a natural or unnatural amino acid; R3 is optionally substituted alkyl, cycloalkyl, phenyl or benzyl; and pharmaceutically acceptable salts and compositions thereof which are useful in the treatment of cancer, especially leukemias.Type: ApplicationFiled: March 8, 2019Publication date: December 24, 2020Inventors: Björn KLASSON, Fredrik ÖBERG
-
Publication number: 20200399296Abstract: A non-aqueous electrolytic solution includes a phosphoric acid diester salt, which can suppress deterioration of charge-discharge characteristics of a power storage element, and can suppress the rise in internal resistance after storage at high temperature. The phosphoric acid diester salt is represented by the following chemical formula (1): in which Mn+ represents a hydrogen ion, an alkali metal ion, an alkali earth metal ion, an aluminum ion, a transition metal ion, or an onium ion, R1 and R2 are different from each other and represent a hydrocarbon group having 1 to 10 carbon atoms, or a hydrocarbon group having 1 to 10 carbon atoms and having at least one of a halogen atom, a heteroatom, and an unsaturated bond, and n represents a valence.Type: ApplicationFiled: September 2, 2020Publication date: December 24, 2020Inventors: Toshitaka SAKAGUCHI, Sojiro KON, Yoshifumi KATSURA, Masashi YAMAMOTO, Tetsuo NISHIDA
-
Publication number: 20200399297Abstract: Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.Type: ApplicationFiled: August 24, 2020Publication date: December 24, 2020Inventors: CAMPBELL MCINNES, SANDRA NAVONNE CRAIG
-
Publication number: 20200399298Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPAType: ApplicationFiled: January 24, 2020Publication date: December 24, 2020Inventors: BARBARA SLUSHER, RANA RAIS, MARCELA KRECMEROVA, TOMAS TICHY, PAVEL MAJER, ANDREJ JANCARIK
-
Publication number: 20200399299Abstract: Described herein are catalytic hydrogenation processes, using Ru complexes with tetradentate ligands of formula L in hydrogenation processes for the reduction of ketone, aldehyde, ester, or lactone into the corresponding alcohol or diol respectively. These processes use a ruthenium complex of formula (1) as defined herein.Type: ApplicationFiled: March 12, 2019Publication date: December 24, 2020Inventors: Philippe DUPAU, Lucia BONOMO, Laurent KERMORVAN, Murielle HALDIMANN SANCHEZ
-
Publication number: 20200399300Abstract: Organometallic compounds useful in chemical phase deposition processes such as atomic layer deposition (ALD) and chemical vapor deposition (CVD).Type: ApplicationFiled: September 2, 2020Publication date: December 24, 2020Applicant: SEASTAR CHEMICALS ULCInventors: Rajesh ODEDRA, Cunhai DONG, Shaun CEMBELLA
-
Publication number: 20200399301Abstract: Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands a disclosed. For example, heterobifunctional inhibitors of E-selectin and galectin-3 are described and pharmaceutical compositions comprising at least one such agent is described.Type: ApplicationFiled: December 28, 2018Publication date: December 24, 2020Applicant: GLYCOMIMETICS, INC.Inventors: John L. MAGNANI, John M. PETERSON, Arun K. SARKAR, Yusufbhai U. VOHRA, Hong-Woon YANG
-
Publication number: 20200399302Abstract: This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma and inflammatory conditions.Type: ApplicationFiled: January 27, 2020Publication date: December 24, 2020Inventors: Philip G. Haydon, Jinbo Lee
-
Publication number: 20200399303Abstract: The present disclosure features useful compositions and methods to treat disorders for which deamination of an adenosine in an mRNA produces a therapeutic result, e.g., in a subject in need thereof.Type: ApplicationFiled: January 22, 2020Publication date: December 24, 2020Inventors: Andrew W. FRALEY, Steven ROBINETTE, Nessan BERMINGHAM, Mallikarjuna Reddy PUTTA
-
Publication number: 20200399304Abstract: Disclosed herein are spherical nucleic acids (SNAs) comprising oligonucleotides comprising one or more modified oligonucleotides, and methods of use thereof. Also disclosed are methods of synthesizing modified oligonucleotides for use in therapeutics, including deoxynucleic guanidine (DNG)-modified oligonucleotides.Type: ApplicationFiled: June 19, 2020Publication date: December 24, 2020Inventors: Chad A. Mirkin, Kacper Skakuj, Katherine E. Bujold
-
Publication number: 20200399305Abstract: To provide novel compounds that are promising as prodrug-type anticancer agents, a compound represented by general formula (I) or a salt thereof is provided.Type: ApplicationFiled: March 4, 2019Publication date: December 24, 2020Applicant: The University of TokyoInventors: Yasuteru URANO, Mako KAMIYA, Kento HAYASHI
-
Publication number: 20200399306Abstract: The present disclosure relates to solid phase synthesis of organic molecules and particularly to highly efficient methods for synthesizing polymers, such as peptides, nucleotides or saccharides, employing solid phase synthesis.Type: ApplicationFiled: March 12, 2019Publication date: December 24, 2020Inventors: Chaim GILON, Moshe BENTOLILA
-
Publication number: 20200399307Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.Type: ApplicationFiled: January 22, 2020Publication date: December 24, 2020Applicant: Genentech, Inc.Inventors: Hui F. LIU, Brian David KELLEY, Deanna E. MYERS, Beth MCCOOEY, Krista Marie PETTY
-
Publication number: 20200399308Abstract: Non-antimicrobial compounds, methods and compositions comprising the same for treating medical conditions associated with pathogenic microorganism in a subject, as well as drug-resistant strains thereof, which are effective in immunopotentiating the pathogenic microorganism to the antimicrobial systems in the subject, and/or act in synergism with exogenous antimicrobial drugs.Type: ApplicationFiled: March 2, 2018Publication date: December 24, 2020Applicant: Technion Research & Development Foundation LimitedInventor: Amram MOR
-
Publication number: 20200399309Abstract: Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X1-X2-X3-X4-X5-X6-X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.Type: ApplicationFiled: September 2, 2020Publication date: December 24, 2020Inventors: Felix Karim, Amos Baruch, Derek Maclean, Kanad Das, Qun Yin
-
Publication number: 20200399310Abstract: The present disclosure provides peptide compositions (e.g., of self-assembling peptides) with particular attributes (e.g., peptide identity, peptide concentration, pH, ionic strength [including salt identity and/or concentration), etc that show particularly useful material properties. The present disclosure also provides technologies for selecting and/or formulating particular peptide compositions useful in specific contexts. In some embodiments, provided peptide compositions have an elevated pH within the range of about 2.5 to about 3.5 and/or an ionic strength that is above that of a corresponding composition of the same peptide, at the same concentration, in water, but is below a critical salt point for the peptide (e.g., so that the composition is not cloudy).Type: ApplicationFiled: May 13, 2020Publication date: December 24, 2020Inventors: Eun Seok Gil, Karl Gilbert, Manav Mehta
-
Publication number: 20200399311Abstract: The present invention relates to novel short chain peptides of formula (I) which can be useful as a vaccine when in conjugation with suitable immunogenic carrier and suitable adjuvant. These are useful for the treatment for the PCSK9 mediated diseases.Type: ApplicationFiled: April 12, 2018Publication date: December 24, 2020Inventors: Mukul JAIN, Suresh GIRI, Rajesh BAHEKAR, Cupta GAURAV, Rajendra CHOPADE
-
Publication number: 20200399312Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.Type: ApplicationFiled: March 2, 2020Publication date: December 24, 2020Inventors: Donald F. HUNT, Andrew NORRIS, Ann Michelle ENGLISH, Jeffrey SHABANOWITZ, William H. HILDERBRAND, Oriana E. HAWKINS
-
Publication number: 20200399313Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.Type: ApplicationFiled: March 2, 2020Publication date: December 24, 2020Inventors: William Jia, Xuexian Bu, I-Fang Lee
-
Publication number: 20200399314Abstract: Peptidyl IL-2R? ligands and compounds comprising the IL-2R? ligands are disclosed. The IL-2R? ligands and compounds such as synthetic monomers, homodimers, or heteromers and recombinant fusion proteins comprising the IL-2R? ligands can be used as targeting or imaging agents, as diagnostics or to treat cancers and autoimmune diseases.Type: ApplicationFiled: June 2, 2020Publication date: December 24, 2020Inventors: WILLIAM J. DOWER, MICHAEL C. NEEDELS, RONALD W. BARRETT, ALICE V. BAKKER, STEVEN E. CWIRLA
-
Publication number: 20200399315Abstract: The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.Type: ApplicationFiled: July 6, 2020Publication date: December 24, 2020Inventors: Kunwar Shailubhai, Stephen Comiskey, Rong Feng, Juncai Bai, Ruoping Zhang, Jun Jia, Junfeng Zhou, Qiao Zhao, Guoqing Zhang
-
Publication number: 20200399316Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.Type: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Inventors: Yutaka Tagaya, Nazli Azimi
-
Publication number: 20200399317Abstract: The template-fixed ?-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for where cancer is mediated or resulting from CXCR4 receptor activityType: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Applicants: UNIVERSITAET ZUERICH, POLYPHOR LTD.Inventors: Daniel OBRECHT, Frank GOMBERT, Steven J. DEMARCO, Christian LUDIN, Jan Wim VRIJBLOED, Kerstin MOEHLE, John-Anthony ROBINSON, Reshmi MUKHERJEE, Heiko HENZE, Barbara ROMAGNOLI
-
Publication number: 20200399318Abstract: Disclosed herein are isolated peptides inhibit activity of a cofactor-independent phosphoglycerate mutase. In some examples, the isolated peptide is 6-20 amino acids long and includes the amino acid sequence of any one of SEQ ID NOs: 1-22 or 54, an analog or derivative thereof, or a pharmaceutically acceptable salt or ester thereof. In some examples, the peptide is a cyclic peptide with an N-terminal ring of 6-15 amino acids (for example, 6-10 amino acids) and a C-terminal linear portion of 1-9 amino acids (for example, 3-8 amino acids. Also disclosed h are methods of treating or inhibiting an infection in a subject, including administering to the subject an effective amount of a composition including one of more of the disclosed peptides, or analogs or derivative thereof, or pharmaceutically acceptable salts or esters thereof.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The University of Tokyo, New England Biolabs, Inc.Inventors: James Inglese, Patricia Dranchak, Ryan MacArthur, Hiroaki Suga, Hao Yu, Clotilde Carlow, Zhiru Li
-
Publication number: 20200399319Abstract: The disclosure provides a class of pH-sensitive, helix/random conformation switchable antimicrobial polypeptide (HRS-AMP) compositions as a single agent to selectively kill bacteria (e.g., H. pylori) under acidic condition in the stomach with diminished bacterial resistance compared to currently used antibiotics. Methods of treating bacterial infections in the stomach are also provided.Type: ApplicationFiled: January 25, 2018Publication date: December 24, 2020Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Jianjun Cheng, Lin-Feng Chen, Menghua Xiong, Yan Bao
-
Publication number: 20200399320Abstract: The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.Type: ApplicationFiled: May 19, 2020Publication date: December 24, 2020Inventors: Jed J.W. WILTZIUS, Stuart A. SIEVERS
-
Publication number: 20200399321Abstract: The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.Type: ApplicationFiled: July 6, 2020Publication date: December 24, 2020Inventors: Aravind Asokan, Mavis Agbandje-McKenna, Long Ping Victor Tse, Brittney Gurda
-
Publication number: 20200399322Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicant: CureVac AGInventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
-
Publication number: 20200399323Abstract: Featured are recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are simian (rhesus) adenoviruses having a low seroprevalence and high immunogenicity (when expressing, e.g., an antigenic polypeptide) relative to other adenoviruses and vectors thereof. Also featured are methods for producing the adenoviruses and methods of treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).Type: ApplicationFiled: December 11, 2018Publication date: December 24, 2020Inventors: Dan H. BAROUCH, Peter ABBINK, Mark Justin IAMPIETRO, Menzo J. E. HAVENGA
-
Publication number: 20200399324Abstract: Compositions having pesticidal activity and methods for their use are provided. Compositions include isolated and recombinant polypeptide sequences having pesticidal activity, recombinant and synthetic nucleic acid molecules encoding the pesticidal polypeptides, DNA constructs comprising the nucleic acid molecules, vectors comprising the nucleic acid molecules, host cells comprising the vectors, and antibodies to the pesticidal polypeptides. Nucleotide sequences encoding the polypeptides provided herein can be used in DNA constructs or expression cassettes for transformation and expression in organisms of interest, including microorganisms and plants. The compositions and methods provided herein are useful for the production of organisms with enhanced pest resistance or tolerance. Transgenic plants and seeds comprising a nucleotide sequence that encodes a pesticidal protein of the invention are also provided. Such plants are resistant to insects and other pests.Type: ApplicationFiled: September 1, 2020Publication date: December 24, 2020Applicant: AGBIOME, INC.Inventors: Jessica Parks, Kira Bulazel Roberts, Rebecca E. Thayer
-
Publication number: 20200399325Abstract: A eukaryotic host cell engineered to produce a heterologous protein of interest (POI), which cell is genetically modified to reduce production of at least one of three different endogenous host cell protein (HCP), and its use in a method of producing the POI.Type: ApplicationFiled: January 30, 2019Publication date: December 24, 2020Inventors: Katrien CLAES, James GRAHAM, Sylwia JOZWIAK, Christoph KIZIAK
-
Publication number: 20200399326Abstract: The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.Type: ApplicationFiled: September 4, 2020Publication date: December 24, 2020Inventors: Penelope R. CHUA, Hanxiao JIANG, Adam Leon MEADOWS
-
Publication number: 20200399327Abstract: The present invention provides methods for treating or alleviating one or more symptoms of depression and/or anxiety in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject. The symptoms of depression and/or anxiety are typically observed in or associated with a neurological condition. The present invention also provides methods for treating a neurological condition such as a psychiatric disorder in a subject comprising administering an effective amount of an NCAM peptide mimetic to the subject.Type: ApplicationFiled: February 7, 2020Publication date: December 24, 2020Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Huda AKIL, Stanley J. WATSON, Cortney TURNER
-
Publication number: 20200399328Abstract: Methods and compositions are provided for improved proteinaceous block copolymer fibers based on long repeat units having molecular weight of greater than about 10 kDal. Each repeat unit includes more than about 150 amino acid residues that are organized into a number of “quasi-repeat units.” The fibers have improved mechanical properties that better recapitulate those of the native silk fibers.Type: ApplicationFiled: July 6, 2020Publication date: December 24, 2020Inventors: David BRESLAUER, Lindsay WRAY, Joshua KITTLESON
-
Publication number: 20200399329Abstract: The invention provides a peptide comprising: a core amino acid sequence, which is identical or similar to the amino acid sequence of a member of the Cecropin family. The invention further provides a nucleic acid sequence encoding the peptide and a vector comprising said nucleic acid. The invention further provides a pharmaceutical composition comprising said peptide or said nucleic acid. The invention further provides methods of treating an infection, overcoming inherent or acquired resistance of a microorganism to an antibiotic agent or disinfecting a wound, the methods comprises administering the peptide to a subject in need thereof.Type: ApplicationFiled: August 6, 2020Publication date: December 24, 2020Inventors: Niv BACHNOFF, Moshe COHEN-KUTNER
-
Publication number: 20200399330Abstract: This invention discloses isolated protein fractions from Apis mellifera royal jelly (RJ) have proven potent efficacy in inhibiting leukemia cell growth and HIV-1 reverse transcriptase (RT) as well as releasing the cellular sialic acid (sialidase catalytic activity). Methods for RJ fractionation, the investigation against leukemia cell lines (NFS-60 and Jurkat cells), HIV-1 RT, and cellular SA are disclosed.Type: ApplicationFiled: September 6, 2018Publication date: December 24, 2020Inventors: Salem Ismaell Salem EL-FIKY, Marwa Muhammad Abu-Serie ALI, Noha Hassan Habashy Mohammad ABD AL-GALIL
-
Publication number: 20200399331Abstract: Disclosed here are compositions comprising a curcuminoid-peptide complex. Also disclosed are methods of preparing a curcuminoid-peptide complex, comprising obtaining a curcuminoid; obtaining a peptide; and mixing the curcuminoid and the peptide in a solvent. Also disclosed are methods of treating a subject, the method comprising identifying a subject in need of treatment of a curcumin-related disorder, and administering to the subject a therapeutic composition comprising a curcuminoid-peptide complex as described. Also disclosed are therapeutic compositions comprising a curcuminoid-peptide complex as described and a pharmaceutically acceptable excipient, diluent, or carrier.Type: ApplicationFiled: September 1, 2020Publication date: December 24, 2020Applicants: Haus Bioceuticals, Inc.Inventors: Adam J. PAYNE, Michael CENTOLA, John CHANCEY
-
Publication number: 20200399332Abstract: The present invention relates to the provision of a recombinant AIM that maintains functions, does not multimerize, and is not inactivated by IgM (e.g., a protein containing an amino acid sequence wherein cysteine at amino acid number 168 of the amino acid sequence shown in SEQ ID NO: 1 is substituted with another amino acid, and the like).Type: ApplicationFiled: October 9, 2018Publication date: December 24, 2020Inventor: Toru Miyazaki
-
Publication number: 20200399333Abstract: Synthetic histatins composed of combinations of functional domains of natural histatins separated by exogenous linkers are described as are methods of using endogenous and synthetic histatins for the treatment of ocular diseases or conditions.Type: ApplicationFiled: September 3, 2020Publication date: December 24, 2020Inventor: Vinay AAKALU
-
Publication number: 20200399334Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: ApplicationFiled: June 30, 2020Publication date: December 24, 2020Inventors: Colette SONG, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
-
Publication number: 20200399335Abstract: Modified polypeptides derived from the pyrin-domain of IFI16 are provided as well as their uses in medicine. Specifically, the polypeptides are provided for use in the treatment of disorders associated with STING activity, including cancer and immunodeficient or auto-immune disorders.Type: ApplicationFiled: February 7, 2019Publication date: December 24, 2020Applicant: Aarhus UniversitetInventors: Martin Roelsgaard Jakobsen, Claus Elsborg Olesen